Third, PLZF(–) CD56bright NK cells were detected in HCMV(+) controls and MS patients and, moreover, IFNβ therapy was associated with increased PLZF(–) CD56bright NK cells in HCMV(–) RRMS. Here, IFNB1 is linked to myeloid sarcoma.